Although IL-10 and TGF-β have also been proposed as potential stand-alone treatments for GVHD, the sustained in-vivo production of IL-35 by i35-Bregs and i35-exosomes provides therapeutic advantage over these biologics which are rapidly cleared in-vivo25, 55. Here, TGFB1 is linked to graft versus host disease.